Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes of Acquired Factor VIII Inhibitors in Cancer Population: A Systematic Review

Heidi Chwan Ko, DO, Cristhiam Rojas Hernandez, MD, Thein Hlaing Oo, MD

Blood (2017) 130 (Supplement 1): 5639.

https://doi.org/10.1182/blood.V130.Suppl_1.5639.5639

Published: 2017

Journal Articles

Acquired Factor VIII Inhibitors: A Single Institution Retrospective, Observational Study

Lela Ruck, MD, Morey A. Blinder, MD, William Berger, MSW

Blood (2016) 128 (22): 4971.

https://doi.org/10.1182/blood.V128.22.4971.4971

Published: 2016

Journal Articles

Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplant: A Retrospective Review

Ibraheem H Motabi, MD, Jingxia Liu, PhD, Camille N. Abboud, MD FACP, Amanda F. Cashen, MD, Keith E. Stockler-Goldstein, MD, Geoffrey L. Uy, MD, Ravi Vij, MD, Peter Westervelt, MD PhD, John F. DiPersio

Blood (2014) 124 (21): 3944.

https://doi.org/10.1182/blood.V124.21.3944.3944

Published: 2014

Journal Articles

Franchini and Lippi. Acquired factor VIII inhibitors. Blood. 2008;112:250-255.

Blood (2009) 113 (21): 5368.

https://doi.org/10.1182/blood-2008-10-186270

Published: 2009

Journal Articles

Rituximab for the Treatment of High Titer Acquired Factor VIII Inhibitor with Long Term Follow up

Shylendra B Sreenivasappa, MD, Margaret Clare Telfer, MD

Blood (2008) 112 (11): 4524.

https://doi.org/10.1182/blood.V112.11.4524.4524

Published: 2008

Journal Articles

Acquired factor VIII inhibitors

Massimo Franchini, Giuseppe Lippi

Blood (2008) 112 (2): 250–255.

https://doi.org/10.1182/blood-2008-03-143586

Published: 2008

Journal Articles

Immune Dysregulation after Hematopoietic Stem Cell Transplantation for Autoimmune Diseases Leading to Development of a Second Autoimmune Disorder: Role of Conditioning Regimen Used?.

Yvonne Loh, MD, Yu Oyama, MD, Laisvyde Statkute, MD, Kathleen Quigley, RN, Kimberly Yaung, RN, Walter Barr, MD, Richard K. Burt, MD

Blood (2006) 108 (11): 760.

https://doi.org/10.1182/blood.V108.11.760.760

Published: 2006

Journal Articles

Rituximab for the Treatment of High Titer Acquired Factor VIII Inhibitors Refractory to Conventional Chemotherapy.

Joshua J. Field, MD, Timothy S. Fenske, MD, Morey A. Blinder, MD

Blood (2005) 106 (11): 3212.

https://doi.org/10.1182/blood.V106.11.3212.3212

Published: 2005

Journal Articles

Rituximab in the treatment of acquired factor VIII inhibitors

Adrian Wiestner, Hearn J. Cho, Adam S. Asch, Mary Ann Michelis, Jack A. Zeller, Ellinor I. B. Peerschke, Babette B. Weksler, Geraldine P. Schechter

Blood (2002) 100 (9): 3426–3428.

https://doi.org/10.1182/blood-2002-03-0765

Published: 2002

NARROW

Clinical Outcomes of Acquired Factor VIII Inhibitors in Cancer Population: A Systematic Review

Acquired Factor VIII Inhibitors: A Single Institution Retrospective, Observational Study

Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplant: A Retrospective Review

Franchini and Lippi. Acquired factor VIII inhibitors. Blood. 2008;112:250-255.

Rituximab for the Treatment of High Titer Acquired Factor VIII Inhibitor with Long Term Follow up

Acquired factor VIII inhibitors

Immune Dysregulation after Hematopoietic Stem Cell Transplantation for Autoimmune Diseases Leading to Development of a Second Autoimmune Disorder: Role of Conditioning Regimen Used?.

Rituximab for the Treatment of High Titer Acquired Factor VIII Inhibitors Refractory to Conventional Chemotherapy.

Rituximab in the treatment of acquired factor VIII inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only